Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongfu Xingshen Ye is a Traditional Chinese Medicine (TCM) herbal formula developed for the treatment and prevention of stroke-associated pneumonia (SAP), particularly in patients suffering from acute intracerebral hemorrhage (AICH). The formula is based on the TCM theory of the "brain-gut-lung" axis, which posits a functional connection between these organ systems. It is designed to "clear the hollow organs" (Tong Fu) to alleviate systemic inflammation and "awaken the spirit" (Xing Shen) to support neurological recovery. Clinical research, primarily led by the Guangzhou University of Chinese Medicine, focuses on the formula's ability to modulate immunological mechanisms and improve clinical outcomes in stroke patients who are at high risk for pulmonary infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongfu Xingshen Ye.